Correlation Between Aerovate Therapeutics and Orgenesis

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Aerovate Therapeutics and Orgenesis at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aerovate Therapeutics and Orgenesis into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Aerovate Therapeutics and Orgenesis, you can compare the effects of market volatilities on Aerovate Therapeutics and Orgenesis and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aerovate Therapeutics with a short position of Orgenesis. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aerovate Therapeutics and Orgenesis.

Diversification Opportunities for Aerovate Therapeutics and Orgenesis

-0.82
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Aerovate and Orgenesis is -0.82. Overlapping area represents the amount of risk that can be diversified away by holding Aerovate Therapeutics and Orgenesis in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Orgenesis and Aerovate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aerovate Therapeutics are associated (or correlated) with Orgenesis. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Orgenesis has no effect on the direction of Aerovate Therapeutics i.e., Aerovate Therapeutics and Orgenesis go up and down completely randomly.

Pair Corralation between Aerovate Therapeutics and Orgenesis

Given the investment horizon of 90 days Aerovate Therapeutics is expected to generate 0.72 times more return on investment than Orgenesis. However, Aerovate Therapeutics is 1.38 times less risky than Orgenesis. It trades about 0.01 of its potential returns per unit of risk. Orgenesis is currently generating about -0.03 per unit of risk. If you would invest  1,665  in Aerovate Therapeutics on August 31, 2024 and sell it today you would lose (1,402) from holding Aerovate Therapeutics or give up 84.2% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy92.78%
ValuesDaily Returns

Aerovate Therapeutics  vs.  Orgenesis

 Performance 
       Timeline  
Aerovate Therapeutics 

Risk-Adjusted Performance

13 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Aerovate Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady basic indicators, Aerovate Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.
Orgenesis 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Orgenesis has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Aerovate Therapeutics and Orgenesis Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Aerovate Therapeutics and Orgenesis

The main advantage of trading using opposite Aerovate Therapeutics and Orgenesis positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aerovate Therapeutics position performs unexpectedly, Orgenesis can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orgenesis will offset losses from the drop in Orgenesis' long position.
The idea behind Aerovate Therapeutics and Orgenesis pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Other Complementary Tools

ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Equity Valuation
Check real value of public entities based on technical and fundamental data